Chitinase 3-like 1 is not a target antigen in patients with multiple sclerosis. (August 2021)

• Record Type: Journal Article
• Authors: Comabella, Manuel; Deutschmann, Claudia; Midaglia, Luciana; Schierack, Peter; Martínez, Júlia; Roggenbuck, Dirk; Montalban, Xavier
• Is Part Of: Multiple sclerosis. Volume 27:Number 9(2021)
• Page Start: 1455
• Page End: 1457
• Publication Date: 2021-08
• Subjects: Chitinase 3-like 1 -- autoantibodies -- serum -- multiple sclerosis -- ELISA; Central nervous system -- Diseases -- Periodicals; Myelin sheath -- Diseases -- Periodicals; Inflammation -- Periodicals; Multiple sclerosis -- Periodicals; Central Nervous System Diseases -- Periodicals; Demyelinating Diseases -- Periodicals; Inflammation -- Periodicals; Multiple Sclerosis -- Periodicals; Système nerveux central -- Maladies -- Périodiques; Gaine de myéline -- Maladies -- Périodiques; Inflammation (Pathologie) -- Périodiques; Sclérose en plaques -- Périodiques; Electronic journals; 616.834005
• DOI: 10.1177/1352458520980141
• Languages: English
• ISSNs: 1352-4585

Abstract

Autoimmunity to chitinase 3-like 1 (CHI3L1) has recently been reported in hepatic and bowel inflammatory conditions. Considering that CHI3L1 plays a role as prognostic biomarker in multiple sclerosis (MS), here we investigated CHI3L1 as potential autoantigenic target in the disease. We determined serum CHI3L1 autoantibodies by enzyme-linked immunosorbent assay (ELISA) in a cohort of 60 untreated MS patients with different clinical forms of the disease and 20 healthy controls (HC). IgG levels to CHI3L1 were similar between patients with relapsing-remitting MS, primary and secondary progressive MS, and HC. These findings do not support a role for CHI3L1 autoantibodies in MS pathogenesis.